用户48783635432019-04-09 14:29
【汇众医疗】Navidea宣布重启NAV3-31的2b期临床试验,此后股价上升13%
$Navidea生物制药(NAVB)$ Navidea根据FDA的反馈,宣布重启对NAV3-31的2b期临床试验计划,评估成像剂Tc99m tilmanocept在类风湿性关节炎患者中的应用。此举促进该公司股价上升了13%。 查看全文网页链接查看全文
艾萨克的猫2018-10-23 23:00
$Navidea Biopharmaceuticals, Inc. (NAVB)$ Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today the company will pr...查看全文
$Navidea生物制药(NAVB)$ DEF 14A Other definitive proxy statements Accession Number: 0001437749-23-027767 Act: 34 Size: 819 KB 网页链接
$Navidea生物制药(NAVB)$ PRE 14A Other preliminary proxy statements Accession Number: 0001437749-23-026010 Act: 34 Size: 824 KB 网页链接
$Navidea生物制药(NAVB)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-23-002611 Act: 33 Size: 1 KB 网页链接
$Navidea生物制药(NAVB)$ S-3 Registration statement under Securities Act of 1933 Accession Number: 0001437749-23-024786 Act: 33 Size: 460 KB 网页链接
$Navidea生物制药(NAVB)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001415889-23-012268 Size: 8 KB 网页链接
$Navidea生物制药(NAVB)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001437749-23-023319 Act: 34 Size: 7 MB 网页链接
$Navidea生物制药(NAVB)$ 8-K Current report, items 5.02 and 9.01 Accession Number: 0001437749-23-022524 Act: 34 Size: 173 KB 网页链接
$Navidea生物制药(NAVB)$ 8-K Current report, items 5.02, 5.07, 8.01, and 9.01 Accession Number: 0001437749-23-021059 Act: 34 Size: 226 KB 网页链接
$Navidea生物制药(NAVB)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001415889-23-011171 Size: 7 KB 网页链接
$Navidea生物制药(NAVB)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-23-011175 Size: 4 KB 网页链接